Sascha Ständer

Dr. Sascha Ständer


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
SSSascha Ständer
Sascha Ständer
SSSonja Ständer
Sonja Ständer
Scabies is a common parasitic skin infestation characterized by severe itch and a heterogenous clinical presentation. Itch, as the cardinal symptom of scabies, is imposing a high burden on affected patients and is often difficult to manage. Decreased life quality and secondary complications, caused by an itch-related disruption of the epidermal barrier and subsequent superinfections, illustrate the need to treat scabies and to understand the underlying mechanisms of itch in respective patients. This review summarizes available data on itch in scabies with a special focus on the clinical aspects and its underlying pathomechanisms.

25 April 2021 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
SSSascha Ständer
Sascha Ständer
CHChristoph M. Hammers
Christoph M. Hammers
AVArtem Vorobyev
Artem Vorobyev
ESEnno Schmidt
Enno Schmidt
DZDetlef Zillikens
Detlef Zillikens
KKKhalaf Kridin
Khalaf Kridin
Background: The influence of cutaneous cellular infiltration on the phenotype of bullous pemphigoid (BP) remains to be established.Objectives: To evaluate the main histopathological characteristics of patients with BP and to assess the association between the composition of lesional inflammatory infiltrate and the various clinical, immunological and immunopathological aspects of the disease.Methods: Retrospective study encompassing patients diagnosed with BP throughout the years 2009–2020 in a specialized tertiary referral centre.Results: The study encompassed 136 patients with BP, of whom 27 (19.9%) demonstrated a cell‐poor inflammatory infiltrate in lesional skin specimens. Overall, 78 (57.4%), 71 (52.2%) and 5 (3.7%) specimens were found to include eosinophil‐predominant, lymphocyte‐predominant and neutrophil‐predominant inflammatory infiltrates, respectively. Relative to the remaining patients with BP, those with an eosinophil‐predominant inflammatory infiltrate had higher (90.8% vs. 77.2%; P = 0.030) whilst those with a cell‐poor inflammatory infiltrate lower (70.3% vs. 88.7%; P = 0.017) seropositivity of anti‐BP180 NC16A IgG. The latter subgroup presented with higher prevalence of mucosal involvement (25.9% vs. 8.3%; P = 0.011) and a non‐inflammatory clinical phenotype (50.0% vs. 17.1%; P = 0.041). Patients with lymphocyte‐predominant inflammatory infiltrate manifested with higher severity BPDAI scores and a lower frequency of the non‐inflammatory subtype (11.1% vs. 36.4%; P = 0.035), whilst those with a neutrophilic infiltrate presented with lower mean (SD) levels of anti‐BP180 NC16A IgG [269.3 (227.6) vs. 722.7 (1499.6) U/mL; P = 0.003].Conclusions: Eosinophil‐predominance and high cellularity in the lesional inflammatory infiltrate of BP skin are associated with increased seropositivity of anti‐BP180 NC16A IgG. Lymphocyte‐predominant infiltrates predict a more severe phenotype, pointing towards a pathogenic role of autoreactive lymphocytes.

20 April 2020 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
SSSascha Ständer
Sascha Ständer
YTYves Trense
Yves Trense
DTDiamant Thaçi
Diamant Thaçi
RLRalf J. Ludwig
Ralf J. Ludwig

25 April 2021 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
SSSascha Ständer
Sascha Ständer
CHChristoph M. Hammers
Christoph M. Hammers
AVArtem Vorobyev
Artem Vorobyev
ESEnno Schmidt
Enno Schmidt
JHJ.E. Hundt
J.E. Hundt
KKKhalaf Kridin
Khalaf Kridin
Background: While clustering of bullous pemphigoid (BP) with neuropsychiatric diseases is well‐established, the clinical and immunological profile of BP patients with this comorbidity remains to be decisively determined.Objectives: To evaluate the burden of neurological and psychiatric comorbidities among patients with BP and to elucidate the clinical, immunological and immunopathological features of patients with BP and comorbid neuropsychiatric conditions.Methods: We performed a retrospective study encompassing patients diagnosed with BP throughout the years 2009–2020 in a specialized tertiary referral centre. Multivariate logistic regression model was used to identify predictors of neuropsychiatric conditions among patients with BP.Results: The study included 273 patients with BP, of whom 123 (45.1%) presented with comorbid neuropsychiatric disease. Compared to the remaining patients with BP (n = 150), those with pre‐existing neuropsychiatric diseases demonstrated older mean [standard deviation (SD)] age [81.7 (9.1) vs. 76.9 (10.1); P < 0.001], female preponderance (65.0% vs. 49.3%; P = 0.009), higher seropositivity rate of anti‐BP230 (67.7% vs. 36.5%; P = 0.006) and higher levels of anti‐BP180 NC16A IgG [651.3 (1279.6) vs. 370.4 (818.6) U/mL; P = 0.039]. In multivariate analysis, anti‐BP230 seropositivity was independently associated with coexistence of BP with neuropsychiatric conditions [adjusted odds ratio (OR), 3.43; 95% CI, 1.24–9.52; P = 0.018]. In a sensitivity analysis confined to patients with neurological diseases (n = 103), older age [82.1 (8.4) vs. 77.2 (10.3); P < 0.001] and increased anti‐BP230 seropositivity (68.0% vs. 39.7%; P = 0.018) were identified.Conclusions: The coexistence of BP with neuropsychiatric diseases is independently associated with the generation of anti‐BP230 antibodies.

17 May 2021 in The Journal of Dermatology
Verified
Journal Article
Open access
PDF file
SSSascha Ständer
Sascha Ständer
MKMichael Kasperkiewicz
Michael Kasperkiewicz
DTDiamant Thaçi
Diamant Thaçi
ESEnno Schmidt
Enno Schmidt
DZDetlef Zillikens
Detlef Zillikens
RLRalf J. Ludwig
Ralf J. Ludwig
Bullous pemphigoid (BP) is an autoimmune skin disease, caused by autoantibodies to BP180 and/or BP230. While both these autoantigens are expressed in the entire skin, only some parts of the body become affected. Rare clinical observations indicate that BP may also manifest locally, usually following exposure to triggers. Here, we evaluated the occurrence and potential triggers of localized BP (LBP) in a cohort of 285 BP patients. Medical records of all BP patients hospitalized between 2009 and 2019 were reviewed. In 7/285 BP patients, a localized variant was identified. In 5/7 LBP patients, the disease remained local, while in 2/7 patients, an initial LBP subsequently spread. All cases were preceded by presumptive triggers, including previously described triggers and bacterial infections. Overall, LBP is rare. LBP, however, might be underdiagnosed and should thus be considered in the differential diagnosis, particularly when trigger factors preceded.

1 May 2020 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
SSSascha Ständer
Sascha Ständer
BFB. Färber
B. Färber
SRS. Radeke
S. Radeke
ESE. Schmidt
E. Schmidt
DZD. Zillikens
D. Zillikens
Ralf J. LudwigRalf J. Ludwig
Ralf J. Ludwig
The autoimmune skin blistering diseases pemphigus (vulgaris and foliaceus) and bullous pemphigoid (BP) pose a high burden on affected patients. With current treatment options, induction of remission is achieved in most patients. However, prolonged immunosuppression is required to maintain remission, and treatment‐related morbidity and mortality further adds to the patients' burden1,2. Hence, development of novel therapeutic strategies that are effective and safe is highly warranted. Recently, insights into pemphigus and BP pathogenesis identified new therapeutic targets and drugs3.